Legacy Capital Wealth Partners LLC lessened its stake in Sanofi (NASDAQ:SNY - Free Report) by 49.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,157 shares of the company's stock after selling 12,117 shares during the quarter. Legacy Capital Wealth Partners LLC's holdings in Sanofi were worth $586,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in the company. Jennison Associates LLC boosted its holdings in Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company's stock worth $109,753,000 after acquiring an additional 1,720,972 shares during the period. Thrivent Financial for Lutherans lifted its position in shares of Sanofi by 28,890.2% during the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company's stock worth $82,366,000 after purchasing an additional 1,424,289 shares in the last quarter. DAVENPORT & Co LLC boosted its stake in shares of Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock valued at $110,715,000 after purchasing an additional 664,455 shares during the period. JPMorgan Chase & Co. grew its holdings in Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock valued at $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock worth $208,106,000 after buying an additional 395,744 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.
Sanofi Stock Up 1.0 %
SNY stock traded up $0.53 during mid-day trading on Thursday, hitting $54.13. 1,144,377 shares of the company were exchanged, compared to its average volume of 2,472,063. The company has a market capitalization of $137.37 billion, a PE ratio of 21.74, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The firm has a fifty day simple moving average of $50.65 and a 200 day simple moving average of $52.49. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on SNY. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $60.00.
Get Our Latest Stock Analysis on Sanofi
Sanofi Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
